Lipidomics studies on macrophages - bone marrow-derived macrophages treated with 25-hydroxy-cholesterol +/- lipid-depleted media containing compactin
Introduction | Browse | DownloadMouse-over the above links for more information
Treatment details
| LM ID | Analyte | Treatment | Time(hrs) | Sample ID | Value | Units |
|---|---|---|---|---|---|---|
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.0 | BCD100427B002 | 13.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 0.5 | BCD100427B005 | 10.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 1.0 | BCD100427B009 | 12.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 2.0 | BCD100427B013 | 8.49 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 4.0 | BCD100427B017 | 8.98 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 8.0 | BCD100427B021 | 11.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 12.0 | BCD100427B025 | 12.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | Lipid-depleted/compactin | 24.0 | BCD100427B029 | 22.7 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.0 | BCD100427B001 | 13.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 0.5 | BCD100427B003 | 10.9 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 1.0 | BCD100427B007 | 11.8 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 2.0 | BCD100427B011 | 8.33 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 4.0 | BCD100427B015 | 10.5 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 8.0 | BCD100427B019 | 11 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 12.0 | BCD100427B023 | 18 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | C | 24.0 | BCD100427B027 | 15.2 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 0.5 | BCD100427B006 | 8.35 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 1.0 | BCD100427B010 | 13.1 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 2.0 | BCD100427B014 | 9.22 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 4.0 | BCD100427B018 | 10 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 8.0 | BCD100427B022 | 15.4 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 12.0 | BCD100427B026 | 11.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol + Lipid-depleted/compactin | 24.0 | BCD100427B030 | 14.9 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 0.5 | BCD100427B004 | 12.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 1.0 | BCD100427B008 | 11.5 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 2.0 | BCD100427B012 | 6.72 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 4.0 | BCD100427B016 | 8.23 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 8.0 | BCD100427B020 | 10.6 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 12.0 | BCD100427B024 | 9.55 | pmol/sample |
| LMFA01030159 | 11,14,17-eicosatrienoic acid | 25OH-Chol | 24.0 | BCD100427B028 | 14.5 | pmol/sample |